// ============================================================
// TERRAIN — Device & Diagnostics Partner Database
// lib/data/device-partner-database.ts
//
// 100+ medtech, diagnostics, and device company profiles
// for the device partner matching engine.
//
// Re-exports existing profiles from device-indications.ts
// and adds additional companies for comprehensive coverage.
//
// Sources: SEC filings, annual reports, press releases,
// MedTech Strategist deal databases (2020-2025)
// ============================================================

import {
  DEVICE_PARTNER_DATABASE as EXISTING_DEVICE_PARTNERS,
  type DevicePartnerProfile,
} from './device-indications';

// Re-export the type
export type { DevicePartnerProfile };

// ────────────────────────────────────────────────────────────
// ADDITIONAL DEVICE & DIAGNOSTICS PARTNERS
// Extends the 11 partners already in device-indications.ts
// ────────────────────────────────────────────────────────────

const ADDITIONAL_DEVICE_PARTNERS: DevicePartnerProfile[] = [

  // ── LARGE MEDTECH ─────────────────────────────────────────

  {
    company: 'Johnson & Johnson MedTech',
    company_type: 'large_medtech',
    hq: 'New Brunswick, NJ',
    market_cap_b: 385,
    revenue_b: 30,
    key_divisions: ['Orthopedics', 'Surgery', 'Interventional Solutions', 'Vision'],
    primary_therapeutic_areas: ['orthopedics', 'general surgery', 'electrophysiology', 'vision care', 'neurovascular'],
    active_bd_interests: ['robotic surgery (OTTAVA)', 'digital surgery', 'electrophysiology (PFA)', 'contact lens technology'],
    recent_acquisitions: ['Abiomed ($16.6B, 2023)', 'Shockwave Medical ($13.1B, 2024)'],
    deal_size_range: '$100M - $16B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'J&J MedTech Annual Report 2024',
  },

  {
    company: 'Becton Dickinson (BD)',
    company_type: 'large_medtech',
    hq: 'Franklin Lakes, NJ',
    market_cap_b: 65,
    revenue_b: 20,
    key_divisions: ['BD Medical', 'BD Life Sciences', 'BD Interventional'],
    primary_therapeutic_areas: ['medication delivery', 'biosurgery', 'peripheral vascular', 'urology', 'diagnostics'],
    active_bd_interests: ['smart connected devices', 'biosurgery innovation', 'advanced drug delivery', 'point-of-care diagnostics'],
    recent_acquisitions: ['Parata Systems ($1.5B, 2022)', 'MedSurg (organic growth)'],
    deal_size_range: '$50M - $5B acquisitions',
    preferred_stage: ['cleared_approved', 'submission_pending'],
    source: 'BD Annual Report 2024',
  },

  {
    company: 'Baxter International',
    company_type: 'large_medtech',
    hq: 'Deerfield, IL',
    market_cap_b: 20,
    revenue_b: 15,
    key_divisions: ['Medical Products & Therapies', 'Healthcare Systems & Technologies', 'Pharmaceuticals'],
    primary_therapeutic_areas: ['renal care', 'medication delivery', 'advanced surgery', 'clinical nutrition', 'acute therapies'],
    active_bd_interests: ['connected infusion systems', 'renal replacement therapy next-gen', 'clinical informatics', 'surgical hemostasis'],
    recent_acquisitions: ['Hillrom ($12.4B, 2022)', 'Kidney Care spinoff (Vantive, 2024)'],
    deal_size_range: '$50M - $12B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Baxter Annual Report 2024',
  },

  {
    company: 'Terumo Corporation',
    company_type: 'large_medtech',
    hq: 'Tokyo, Japan (US: Somerset, NJ)',
    market_cap_b: 25,
    revenue_b: 6.8,
    key_divisions: ['Cardiac & Vascular (TCV)', 'Terumo Blood & Cell Technologies', 'Medical Care Solutions'],
    primary_therapeutic_areas: ['cardiovascular', 'vascular', 'blood management', 'interventional'],
    active_bd_interests: ['drug-coated devices', 'interventional neurovascular', 'cell therapy processing', 'radial access PCI'],
    recent_acquisitions: ['Quirem Medical (radioembolization, 2020)', 'Biovitals (remote monitoring, 2021)'],
    deal_size_range: '$100M - $3B acquisitions',
    preferred_stage: ['pivotal_ongoing', 'cleared_approved'],
    source: 'Terumo Annual Report 2024',
  },

  {
    company: 'Smith+Nephew',
    company_type: 'large_medtech',
    hq: 'London, UK',
    market_cap_b: 11,
    revenue_b: 5.6,
    key_divisions: ['Orthopedics', 'Sports Medicine', 'Advanced Wound Management'],
    primary_therapeutic_areas: ['joint replacement', 'sports medicine', 'trauma', 'wound care', 'ENT'],
    active_bd_interests: ['robotic-assisted surgery (CORI)', 'regenerative medicine', 'advanced wound care technology', 'digital surgery'],
    recent_acquisitions: ['Integra LifeSciences (wound care, $1.1B, discussed 2024)'],
    deal_size_range: '$50M - $3B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Smith+Nephew Annual Report 2024',
  },

  {
    company: 'Hologic',
    company_type: 'large_medtech',
    hq: 'Marlborough, MA',
    market_cap_b: 20,
    revenue_b: 4.0,
    key_divisions: ['Diagnostics', 'Breast Health', 'GYN Surgical', 'Skeletal Health'],
    primary_therapeutic_areas: ['women\'s health', 'breast imaging', 'molecular diagnostics', 'GYN surgery', 'STI testing'],
    active_bd_interests: ['AI-powered breast imaging', 'molecular diagnostics expansion', 'point-of-care STI testing', 'liquid biopsy women\'s health'],
    recent_acquisitions: ['Bolder Surgical ($200M, 2022)', 'Biotheranostics ($230M, 2021)'],
    deal_size_range: '$50M - $2B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_design'],
    source: 'Hologic Annual Report 2024',
  },

  {
    company: 'Philips',
    company_type: 'large_medtech',
    hq: 'Amsterdam, Netherlands',
    market_cap_b: 22,
    revenue_b: 18,
    key_divisions: ['Diagnosis & Treatment', 'Connected Care', 'Personal Health'],
    primary_therapeutic_areas: ['radiology', 'ultrasound', 'image-guided therapy', 'patient monitoring', 'sleep/respiratory'],
    active_bd_interests: ['AI radiology', 'precision diagnosis', 'tele-ICU', 'cardiac ultrasound', 'image-guided minimally invasive procedures'],
    recent_acquisitions: ['BioTelemetry ($2.8B, 2021)', 'Capsule Technologies ($635M, 2021)'],
    deal_size_range: '$100M - $3B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Philips Annual Report 2024',
  },

  {
    company: 'GE HealthCare',
    company_type: 'large_medtech',
    hq: 'Chicago, IL',
    market_cap_b: 42,
    revenue_b: 19.6,
    key_divisions: ['Imaging', 'Ultrasound', 'Patient Care Solutions', 'Pharmaceutical Diagnostics'],
    primary_therapeutic_areas: ['radiology', 'ultrasound', 'patient monitoring', 'contrast agents', 'theranostics'],
    active_bd_interests: ['AI-powered imaging', 'theranostics', 'point-of-care ultrasound', 'photon-counting CT', 'clinical decision support'],
    recent_acquisitions: ['Caption Health AI ($200M, 2023)', 'IMACTIS (CT navigation, 2024)'],
    deal_size_range: '$100M - $5B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'GE HealthCare Annual Report 2024',
  },

  // ── MID-SIZE MEDTECH ──────────────────────────────────────

  {
    company: 'Integra LifeSciences',
    company_type: 'mid_medtech',
    hq: 'Princeton, NJ',
    market_cap_b: 3,
    revenue_b: 1.6,
    key_divisions: ['Codman Specialty Surgical', 'Tissue Technologies'],
    primary_therapeutic_areas: ['neurosurgery', 'spine', 'wound care', 'reconstructive surgery'],
    active_bd_interests: ['neurosurgical instruments', 'dural repair', 'regenerative wound care', 'CereLink brain monitoring'],
    recent_acquisitions: ['Surgical Innovation Associates ($400M, 2022)'],
    deal_size_range: '$50M - $1B acquisitions',
    preferred_stage: ['cleared_approved', 'submission_pending'],
    source: 'Integra Annual Report 2024',
  },

  {
    company: 'ICU Medical',
    company_type: 'mid_medtech',
    hq: 'San Clemente, CA',
    market_cap_b: 3,
    revenue_b: 2.4,
    key_divisions: ['Infusion Therapy', 'Critical Care', 'IV Solutions'],
    primary_therapeutic_areas: ['infusion systems', 'IV therapy', 'critical care', 'oncology infusion'],
    active_bd_interests: ['smart infusion pumps', 'IV safety technology', 'oncology drug delivery', 'closed-system transfer devices'],
    recent_acquisitions: ['Smiths Medical ($2.4B, 2022)'],
    deal_size_range: '$50M - $2.5B acquisitions',
    preferred_stage: ['cleared_approved'],
    source: 'ICU Medical Annual Report 2024',
  },

  {
    company: 'Insulet Corporation',
    company_type: 'mid_medtech',
    hq: 'Acton, MA',
    market_cap_b: 18,
    revenue_b: 2.1,
    key_divisions: ['Omnipod (insulin delivery)'],
    primary_therapeutic_areas: ['diabetes', 'insulin delivery', 'automated insulin dosing'],
    active_bd_interests: ['closed-loop AID systems', 'CGM integration', 'Type 2 diabetes expansion', 'digital health diabetes management'],
    recent_acquisitions: ['Automated Glucose Control (internal R&D focused)'],
    deal_size_range: '$20M - $1B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Insulet Annual Report 2024',
  },

  {
    company: 'Tandem Diabetes Care',
    company_type: 'mid_medtech',
    hq: 'San Diego, CA',
    market_cap_b: 3,
    revenue_b: 0.9,
    key_divisions: ['Insulin Pump Systems', 'Automated Insulin Delivery'],
    primary_therapeutic_areas: ['diabetes', 'insulin pump', 'automated insulin delivery'],
    active_bd_interests: ['Mobi pump (smallest pump)', 'CGM agnostic integration', 'Type 2 diabetes expansion', 'predictive algorithms'],
    recent_acquisitions: ['AMF Medical (Swiss insulin delivery startup, 2022)'],
    deal_size_range: '$20M - $500M acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Tandem Annual Report 2024',
  },

  {
    company: 'iRhythm Technologies',
    company_type: 'mid_medtech',
    hq: 'San Francisco, CA',
    market_cap_b: 3,
    revenue_b: 0.5,
    key_divisions: ['Zio XT', 'Zio AT', 'Zio ECG'],
    primary_therapeutic_areas: ['cardiac monitoring', 'arrhythmia detection', 'ambulatory ECG'],
    active_bd_interests: ['AI-based arrhythmia detection', 'continuous cardiac monitoring', 'remote patient monitoring', 'AF screening'],
    recent_acquisitions: ['Internal R&D focused; selective acquisitions'],
    deal_size_range: '$10M - $500M acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_design'],
    source: 'iRhythm Annual Report 2024',
  },

  {
    company: 'Masimo Corporation',
    company_type: 'mid_medtech',
    hq: 'Irvine, CA',
    market_cap_b: 8,
    revenue_b: 2.3,
    key_divisions: ['Healthcare', 'Non-Healthcare (Sound United)'],
    primary_therapeutic_areas: ['pulse oximetry', 'patient monitoring', 'brain monitoring', 'capnography'],
    active_bd_interests: ['hospital automation', 'continuous monitoring', 'tetherless patient monitoring', 'hemodynamic sensing'],
    recent_acquisitions: ['Sound United ($1.0B, 2022)', 'NantHealth (patient safety, 2023)'],
    deal_size_range: '$50M - $1B acquisitions',
    preferred_stage: ['cleared_approved'],
    source: 'Masimo Annual Report 2024',
  },

  {
    company: 'Haemonetics',
    company_type: 'mid_medtech',
    hq: 'Boston, MA',
    market_cap_b: 4,
    revenue_b: 1.3,
    key_divisions: ['Plasma', 'Blood Center', 'Hospital'],
    primary_therapeutic_areas: ['blood management', 'plasma collection', 'cell salvage', 'hemostasis'],
    active_bd_interests: ['next-gen plasma collection', 'TEG hemostasis management', 'blood safety', 'digital blood banking'],
    recent_acquisitions: ['Attune Medical ($160M, 2023)', 'OpSens (vascular FFR, $300M, 2023)'],
    deal_size_range: '$50M - $500M acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Haemonetics Annual Report 2024',
  },

  {
    company: 'Penumbra',
    company_type: 'mid_medtech',
    hq: 'Alameda, CA',
    market_cap_b: 3,
    revenue_b: 1.0,
    key_divisions: ['Neuro', 'Vascular'],
    primary_therapeutic_areas: ['neurovascular', 'stroke thrombectomy', 'peripheral vascular', 'deep vein thrombosis'],
    active_bd_interests: ['AI-guided stroke treatment', 'next-gen aspiration thrombectomy', 'peripheral vascular intervention'],
    recent_acquisitions: ['Internal R&D focused on neuro innovation'],
    deal_size_range: '$20M - $500M acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Penumbra Annual Report 2024',
  },

  {
    company: 'Globus Medical',
    company_type: 'mid_medtech',
    hq: 'Audubon, PA',
    market_cap_b: 10,
    revenue_b: 2.4,
    key_divisions: ['Musculoskeletal Solutions', 'Enabling Technologies'],
    primary_therapeutic_areas: ['spine', 'trauma', 'robotics (ExcelsiusGPS)'],
    active_bd_interests: ['robotic-assisted spine surgery', 'AI surgical planning', 'trauma fixation', 'biologics for spine'],
    recent_acquisitions: ['NuVasive ($3.1B merger, 2023)'],
    deal_size_range: '$50M - $3B acquisitions',
    preferred_stage: ['cleared_approved', 'submission_pending'],
    source: 'Globus Medical Annual Report 2024',
  },

  {
    company: 'Alphatec Holdings',
    company_type: 'mid_medtech',
    hq: 'Carlsbad, CA',
    market_cap_b: 2,
    revenue_b: 0.7,
    key_divisions: ['Spine Surgery Solutions', 'EOS Imaging'],
    primary_therapeutic_areas: ['spine', 'lateral surgery', 'navigation', 'patient positioning'],
    active_bd_interests: ['lateral spine innovation', 'informatics-driven surgery', 'prone positioning technology'],
    recent_acquisitions: ['EOS Imaging ($355M, 2022)', 'SafeOp Surgical ($120M, 2021)'],
    deal_size_range: '$20M - $500M acquisitions',
    preferred_stage: ['cleared_approved'],
    source: 'Alphatec Annual Report 2024',
  },

  {
    company: 'Inari Medical',
    company_type: 'mid_medtech',
    hq: 'Irvine, CA',
    market_cap_b: 3,
    revenue_b: 0.5,
    key_divisions: ['Venous Thromboembolism'],
    primary_therapeutic_areas: ['PE thrombectomy', 'DVT treatment', 'venous disease'],
    active_bd_interests: ['mechanical thrombectomy', 'chronic venous disease', 'limb salvage', 'PE intervention'],
    recent_acquisitions: ['LimFlow ($200M, discussed 2024)'],
    deal_size_range: '$20M - $500M acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Inari Annual Report 2024',
  },

  {
    company: 'Shockwave Medical (J&J)',
    company_type: 'mid_medtech',
    hq: 'Santa Clara, CA (now J&J MedTech)',
    market_cap_b: 385,
    revenue_b: 0.8,
    key_divisions: ['Intravascular Lithotripsy'],
    primary_therapeutic_areas: ['coronary calcification', 'peripheral calcification', 'aortic stenosis'],
    active_bd_interests: ['IVL technology extension', 'coronary intervention', 'structural heart'],
    recent_acquisitions: ['Acquired by J&J ($13.1B, 2024)'],
    deal_size_range: '$50M - $13B',
    preferred_stage: ['cleared_approved'],
    source: 'J&J MedTech Reports 2024',
  },

  {
    company: 'Axonics (Boston Scientific)',
    company_type: 'mid_medtech',
    hq: 'Irvine, CA (now Boston Scientific)',
    market_cap_b: 120,
    revenue_b: 0.4,
    key_divisions: ['Sacral Neuromodulation'],
    primary_therapeutic_areas: ['overactive bladder', 'urinary incontinence', 'fecal incontinence'],
    active_bd_interests: ['rechargeable SNM', 'next-gen neuromodulation', 'OAB digital health'],
    recent_acquisitions: ['Acquired by Boston Scientific ($3.7B, 2024)'],
    deal_size_range: '$50M - $4B',
    preferred_stage: ['cleared_approved'],
    source: 'Boston Scientific Reports 2024',
  },

  {
    company: 'Nevro',
    company_type: 'mid_medtech',
    hq: 'Redwood City, CA',
    market_cap_b: 1,
    revenue_b: 0.4,
    key_divisions: ['High Frequency Spinal Cord Stimulation'],
    primary_therapeutic_areas: ['chronic pain', 'spinal cord stimulation', 'diabetic neuropathy', 'nonsurgical refractory back pain'],
    active_bd_interests: ['HFX iQ AI-guided SCS', 'diabetic neuropathy expansion', 'closed-loop SCS', 'new pain indications'],
    recent_acquisitions: ['Internal R&D focused'],
    deal_size_range: '$10M - $500M acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Nevro Annual Report 2024',
  },

  {
    company: 'Procept BioRobotics',
    company_type: 'mid_medtech',
    hq: 'Redwood City, CA',
    market_cap_b: 4,
    revenue_b: 0.2,
    key_divisions: ['Aquablation (robotic water ablation)'],
    primary_therapeutic_areas: ['urology', 'BPH treatment', 'robotic surgery'],
    active_bd_interests: ['Aquablation next-gen', 'BPH market expansion', 'office-based procedures'],
    recent_acquisitions: ['Internal R&D focused on AquaBeam platform'],
    deal_size_range: '$10M - $500M acquisitions',
    preferred_stage: ['cleared_approved'],
    source: 'Procept Annual Report 2024',
  },

  {
    company: 'TransMedics',
    company_type: 'mid_medtech',
    hq: 'Andover, MA',
    market_cap_b: 4,
    revenue_b: 0.4,
    key_divisions: ['Organ Care System (OCS)'],
    primary_therapeutic_areas: ['organ transplant', 'ex vivo organ perfusion', 'heart/lung/liver transplant'],
    active_bd_interests: ['National OCS Program (NOP)', 'organ utilization expansion', 'logistics integration'],
    recent_acquisitions: ['Pioneer Aviation (organ transport logistics, 2022)'],
    deal_size_range: '$20M - $500M acquisitions',
    preferred_stage: ['cleared_approved'],
    source: 'TransMedics Annual Report 2024',
  },

  {
    company: 'ClearPoint Neuro',
    company_type: 'mid_medtech',
    hq: 'Solana Beach, CA',
    market_cap_b: 0.3,
    revenue_b: 0.03,
    key_divisions: ['ClearPoint Navigation System', 'Biologics & Drug Delivery'],
    primary_therapeutic_areas: ['neurosurgery', 'gene therapy delivery', 'DBS placement', 'laser ablation guidance'],
    active_bd_interests: ['MRI-guided drug delivery to brain', 'gene therapy CNS delivery platform', 'stereotactic navigation'],
    recent_acquisitions: ['Internal R&D; focus on platform partnerships with gene therapy companies'],
    deal_size_range: '$5M - $200M partnerships',
    preferred_stage: ['feasibility', 'pivotal_design'],
    source: 'ClearPoint Neuro Annual Report 2024',
  },

  {
    company: 'Silk Road Medical',
    company_type: 'mid_medtech',
    hq: 'Sunnyvale, CA',
    market_cap_b: 1,
    revenue_b: 0.2,
    key_divisions: ['TCAR (transcarotid artery revascularization)'],
    primary_therapeutic_areas: ['carotid artery disease', 'stroke prevention', 'vascular surgery'],
    active_bd_interests: ['TCAR procedure expansion', 'neuroprotection', 'carotid stenting'],
    recent_acquisitions: ['Boston Scientific acquisition ($1.16B, 2024)'],
    deal_size_range: '$20M - $1B',
    preferred_stage: ['cleared_approved'],
    source: 'Boston Scientific Reports 2024',
  },

  {
    company: 'Natus Medical (Integra)',
    company_type: 'mid_medtech',
    hq: 'Middleton, WI',
    market_cap_b: 3,
    revenue_b: 0.5,
    key_divisions: ['Neurology Diagnostics', 'Newborn Care', 'Hearing Assessment'],
    primary_therapeutic_areas: ['EEG monitoring', 'newborn screening', 'hearing diagnostics', 'sleep diagnostics'],
    active_bd_interests: ['cloud-based EEG', 'AI seizure detection', 'neonatal monitoring', 'hearing implants'],
    recent_acquisitions: ['Acquired by Integra LifeSciences ($1.4B, 2022, later reviewed)'],
    deal_size_range: '$20M - $1.5B',
    preferred_stage: ['cleared_approved'],
    source: 'Integra/Natus Reports 2024',
  },

  {
    company: 'Cardiovascular Systems (Abbott)',
    company_type: 'mid_medtech',
    hq: 'St. Paul, MN (now Abbott)',
    market_cap_b: 180,
    revenue_b: 0.3,
    key_divisions: ['Orbital Atherectomy'],
    primary_therapeutic_areas: ['peripheral atherectomy', 'coronary atherectomy', 'calcified lesions'],
    active_bd_interests: ['atherectomy innovation', 'calcified coronary treatment'],
    recent_acquisitions: ['Acquired by Abbott ($890M, 2023)'],
    deal_size_range: '$50M - $1B',
    preferred_stage: ['cleared_approved'],
    source: 'Abbott Reports 2024',
  },

  {
    company: 'Canary Medical',
    company_type: 'mid_medtech',
    hq: 'Vancouver, BC, Canada',
    market_cap_b: 0.1,
    revenue_b: 0.01,
    key_divisions: ['Smart Implant Sensors'],
    primary_therapeutic_areas: ['orthopedics', 'smart implants', 'remote monitoring'],
    active_bd_interests: ['sensor-embedded joint replacements', 'data-driven orthopedic outcomes', 'RPM for implants'],
    recent_acquisitions: ['Internal R&D focused on CANTURIO sensor platform'],
    deal_size_range: '$5M - $200M partnerships',
    preferred_stage: ['cleared_approved', 'pivotal_design'],
    source: 'Canary Medical corporate filings 2024',
  },

  // ── DIAGNOSTICS COMPANIES ─────────────────────────────────

  {
    company: 'bioMerieux',
    company_type: 'diagnostics_major',
    hq: 'Marcy-l\'Etoile, France',
    market_cap_b: 14,
    revenue_b: 3.9,
    key_divisions: ['Clinical Diagnostics', 'Industrial Microbiology'],
    primary_therapeutic_areas: ['microbiology', 'infectious disease diagnostics', 'blood culture', 'antibiotic susceptibility', 'syndromic testing'],
    active_bd_interests: ['rapid AST', 'AI microbiology', 'syndromic panel expansion', 'sepsis management', 'mass spectrometry'],
    recent_acquisitions: ['Specific Diagnostics ($100M, 2022)', 'Hybiome Biotech (2023)'],
    deal_size_range: '$20M - $1B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_design'],
    source: 'bioMerieux Annual Report 2024',
  },

  {
    company: 'Qiagen',
    company_type: 'diagnostics_major',
    hq: 'Hilden, Germany',
    market_cap_b: 10,
    revenue_b: 2.0,
    key_divisions: ['Sample Technologies', 'Diagnostic Solutions', 'PCR/Genomics'],
    primary_therapeutic_areas: ['molecular diagnostics', 'sample preparation', 'HPV testing', 'TB diagnostics', 'companion diagnostics'],
    active_bd_interests: ['digital PCR', 'companion diagnostic partnerships', 'NGS sample prep', 'point-of-care molecular testing'],
    recent_acquisitions: ['NeuMoDx Molecular (2020)', 'Veridex assets'],
    deal_size_range: '$20M - $1B acquisitions',
    preferred_stage: ['feasibility', 'pivotal_design', 'cleared_approved'],
    source: 'Qiagen Annual Report 2024',
  },

  {
    company: 'Resolution Bioscience (Agilent)',
    company_type: 'diagnostics_specialty',
    hq: 'Kirkland, WA (now Agilent)',
    market_cap_b: 38,
    revenue_b: 0.2,
    key_divisions: ['ctDNA Assays', 'Hybrid Capture NGS', 'Liquid Biopsy'],
    primary_therapeutic_areas: ['oncology genomic profiling', 'liquid biopsy ctDNA', 'companion diagnostics'],
    active_bd_interests: ['ctDNA-based companion diagnostics', 'minimal residual disease', 'pharma CDx development', 'hybridization-capture NGS'],
    recent_acquisitions: ['Acquired by Agilent (2021)'],
    deal_size_range: 'CDx partnerships $5M-$100M per program',
    preferred_stage: ['feasibility', 'pivotal_design', 'cleared_approved'],
    source: 'Agilent / Resolution Bio 2024',
  },

  {
    company: 'Invitae',
    company_type: 'diagnostics_specialty',
    hq: 'San Francisco, CA',
    market_cap_b: 0.2,
    revenue_b: 0.5,
    key_divisions: ['Clinical Genetic Testing', 'Rare Disease', 'Reproductive Health', 'Somatic (oncology)'],
    primary_therapeutic_areas: ['genetic testing', 'hereditary cancer', 'rare disease diagnostics', 'carrier screening', 'prenatal testing'],
    active_bd_interests: ['rare disease gene panels', 'pharmacogenomics', 'AI-guided variant interpretation', 'NIPT expansion'],
    recent_acquisitions: ['ArcherDx ($1.4B, 2020)', 'GeneDx ($150M, divested 2023)'],
    deal_size_range: '$10M - $1B',
    preferred_stage: ['feasibility', 'cleared_approved'],
    source: 'Invitae Annual Report 2024',
  },

  {
    company: 'Myriad Genetics',
    company_type: 'diagnostics_specialty',
    hq: 'Salt Lake City, UT',
    market_cap_b: 3,
    revenue_b: 0.8,
    key_divisions: ['Hereditary Cancer', 'Tumor Profiling', 'Prenatal', 'Pharmacogenomics', 'Autoimmune'],
    primary_therapeutic_areas: ['hereditary cancer (BRCA)', 'tumor profiling', 'prenatal screening', 'pharmacogenomics', 'mental health'],
    active_bd_interests: ['MyChoice CDx expansion', 'GeneSight pharmacogenomics growth', 'AI variant interpretation', 'liquid biopsy MRD'],
    recent_acquisitions: ['Gateway Genomics ($50M, 2021)'],
    deal_size_range: '$10M - $500M acquisitions',
    preferred_stage: ['feasibility', 'pivotal_design', 'cleared_approved'],
    source: 'Myriad Annual Report 2024',
  },

  {
    company: 'Tempus AI',
    company_type: 'diagnostics_specialty',
    hq: 'Chicago, IL',
    market_cap_b: 6,
    revenue_b: 0.6,
    key_divisions: ['Genomics', 'Data & AI', 'Clinical Trial Matching'],
    primary_therapeutic_areas: ['oncology genomics', 'AI-based clinical decision support', 'clinical trial matching', 'real-world data'],
    active_bd_interests: ['multimodal AI diagnostics', 'pharma data partnerships', 'clinical trial optimization', 'pan-cancer profiling'],
    recent_acquisitions: ['Highmark (AI partnership)', 'Internal platform growth'],
    deal_size_range: '$10M - $500M partnerships',
    preferred_stage: ['feasibility', 'pivotal_design'],
    source: 'Tempus Annual Report 2024',
  },

  {
    company: 'Veracyte',
    company_type: 'diagnostics_specialty',
    hq: 'South San Francisco, CA',
    market_cap_b: 3,
    revenue_b: 0.4,
    key_divisions: ['Thyroid (Afirma)', 'Pulmonary (Percepta)', 'Lymphoma (Lymphmark)', 'Prostate (Decipher)'],
    primary_therapeutic_areas: ['thyroid cancer diagnostics', 'lung cancer', 'prostate cancer', 'lymphoma classification', 'genomic diagnostics'],
    active_bd_interests: ['multi-cancer genomic tests', 'AI-driven diagnostics', 'international expansion', 'CDx partnerships'],
    recent_acquisitions: ['Decipher Biosciences ($600M, 2021)', 'HalioDx ($260M, 2021)'],
    deal_size_range: '$20M - $600M acquisitions',
    preferred_stage: ['feasibility', 'pivotal_design', 'cleared_approved'],
    source: 'Veracyte Annual Report 2024',
  },

  {
    company: 'NeoGenomics',
    company_type: 'diagnostics_specialty',
    hq: 'Fort Myers, FL',
    market_cap_b: 2,
    revenue_b: 0.6,
    key_divisions: ['Clinical Services', 'Pharma Services', 'Advanced Diagnostics'],
    primary_therapeutic_areas: ['oncology diagnostics', 'hematopathology', 'flow cytometry', 'FISH/IHC', 'NGS profiling'],
    active_bd_interests: ['pharma clinical trial testing', 'MRD monitoring', 'liquid biopsy integration', 'AI-based pathology'],
    recent_acquisitions: ['Inivata ($390M, 2021)', 'Trapelo (clinical decision support, 2022)'],
    deal_size_range: '$10M - $400M acquisitions',
    preferred_stage: ['feasibility', 'pivotal_design'],
    source: 'NeoGenomics Annual Report 2024',
  },

  {
    company: 'Natera',
    company_type: 'diagnostics_specialty',
    hq: 'Austin, TX',
    market_cap_b: 14,
    revenue_b: 1.2,
    key_divisions: ['Women\'s Health (Panorama)', 'Oncology (Signatera)', 'Organ Health (Prospera)'],
    primary_therapeutic_areas: ['NIPT', 'MRD monitoring (ctDNA)', 'organ transplant rejection', 'oncology liquid biopsy'],
    active_bd_interests: ['Signatera MRD expansion', 'pharma MRD trial partnerships', 'renal transplant monitoring', 'early cancer detection'],
    recent_acquisitions: ['Eurofins Viracor ($69M, 2023)'],
    deal_size_range: '$10M - $500M acquisitions / partnerships',
    preferred_stage: ['feasibility', 'pivotal_design', 'cleared_approved'],
    source: 'Natera Annual Report 2024',
  },

  {
    company: 'Grail (Illumina)',
    company_type: 'diagnostics_specialty',
    hq: 'Menlo Park, CA',
    market_cap_b: 0,
    revenue_b: 0.1,
    key_divisions: ['Galleri (multi-cancer early detection)'],
    primary_therapeutic_areas: ['multi-cancer early detection (MCED)', 'methylation-based ctDNA', 'cancer screening'],
    active_bd_interests: ['MCED clinical validation', 'payer coverage strategy', 'international expansion', 'NHS partnership'],
    recent_acquisitions: ['Re-spun out from Illumina (2024)'],
    deal_size_range: '$50M - $5B',
    preferred_stage: ['feasibility', 'pivotal_ongoing', 'cleared_approved'],
    source: 'Grail corporate communications 2024',
  },

  {
    company: 'Illumina',
    company_type: 'diagnostics_major',
    hq: 'San Diego, CA',
    market_cap_b: 22,
    revenue_b: 4.5,
    key_divisions: ['Sequencing Platforms', 'Consumables', 'Clinical Genomics'],
    primary_therapeutic_areas: ['NGS platforms', 'clinical genomics', 'oncology CDx', 'reproductive health', 'rare disease'],
    active_bd_interests: ['NovaSeq X adoption', 'clinical DRAGEN analysis', 'CDx partnerships', 'multi-omics integration'],
    recent_acquisitions: ['GRAIL divestiture (2024)', 'Pacific Biosciences (partnership discussions)'],
    deal_size_range: '$50M - $8B',
    preferred_stage: ['feasibility', 'pivotal_design', 'cleared_approved'],
    source: 'Illumina Annual Report 2024',
  },

  {
    company: 'Danaher (Beckman Coulter)',
    company_type: 'diagnostics_major',
    hq: 'Washington, DC',
    market_cap_b: 190,
    revenue_b: 24,
    key_divisions: ['Diagnostics (Beckman Coulter, Leica, Cepheid, Radiometer)', 'Life Sciences (Pall, Cytiva)', 'Bioprocessing'],
    primary_therapeutic_areas: ['clinical chemistry', 'immunoassay', 'molecular diagnostics (Cepheid)', 'histopathology', 'blood gas'],
    active_bd_interests: ['point-of-care molecular (GeneXpert)', 'AI pathology', 'bioprocessing automation', 'clinical informatics'],
    recent_acquisitions: ['Abcam ($5.7B, 2023)', 'Cepheid integration (acquired 2016)'],
    deal_size_range: '$100M - $20B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Danaher Annual Report 2024',
  },

  {
    company: 'DiaSorin',
    company_type: 'diagnostics_specialty',
    hq: 'Saluggia, Italy',
    market_cap_b: 5,
    revenue_b: 1.1,
    key_divisions: ['Immunodiagnostics', 'Molecular Diagnostics (Luminex)'],
    primary_therapeutic_areas: ['infectious disease', 'vitamin D', 'hepatitis', 'GI pathogens', 'multiplexed immunoassay'],
    active_bd_interests: ['multiplexed testing', 'LIAISON XL automation', 'molecular diagnostics integration', 'point-of-care'],
    recent_acquisitions: ['Luminex ($1.8B, 2021)'],
    deal_size_range: '$20M - $2B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_design'],
    source: 'DiaSorin Annual Report 2024',
  },

  {
    company: 'Bio-Techne',
    company_type: 'diagnostics_specialty',
    hq: 'Minneapolis, MN',
    market_cap_b: 10,
    revenue_b: 1.1,
    key_divisions: ['Protein Sciences', 'Diagnostics & Genomics (ACD/Exosome Diagnostics)'],
    primary_therapeutic_areas: ['spatial biology', 'IHC/ISH', 'exosome diagnostics', 'protein reagents'],
    active_bd_interests: ['spatial transcriptomics', 'exosome-based liquid biopsy', 'CDx biomarker assays', 'proteomics'],
    recent_acquisitions: ['Lunaphore ($210M, 2024)', 'Agilent Genomics (select assets)'],
    deal_size_range: '$20M - $500M acquisitions',
    preferred_stage: ['feasibility', 'pivotal_design'],
    source: 'Bio-Techne Annual Report 2024',
  },

  {
    company: 'Adaptive Biotechnologies',
    company_type: 'diagnostics_specialty',
    hq: 'Seattle, WA',
    market_cap_b: 1,
    revenue_b: 0.2,
    key_divisions: ['Immune Medicine (clonoSEQ)', 'Drug Discovery (with Genentech)'],
    primary_therapeutic_areas: ['MRD monitoring (myeloma, ALL, CLL)', 'immune repertoire profiling', 'T-cell receptor analysis'],
    active_bd_interests: ['MRD expansion to solid tumors', 'immune profiling for IO trials', 'TCR-antigen mapping for vaccine/cell therapy'],
    recent_acquisitions: ['Internal R&D focused; Genentech partnership ($300M+)'],
    deal_size_range: '$10M - $500M partnerships',
    preferred_stage: ['feasibility', 'cleared_approved'],
    source: 'Adaptive Annual Report 2024',
  },

  {
    company: 'Fulgent Genetics',
    company_type: 'diagnostics_specialty',
    hq: 'Temple City, CA',
    market_cap_b: 1,
    revenue_b: 0.3,
    key_divisions: ['Clinical Genomics', 'Pharma Services'],
    primary_therapeutic_areas: ['rare disease genetic testing', 'oncology NGS', 'pharmacogenomics', 'reproductive genetics'],
    active_bd_interests: ['WGS clinical testing', 'pharma genomics services', 'CDx development', 'population genomics'],
    recent_acquisitions: ['CSI Laboratories ($75M, 2022)', 'Inform Diagnostics ($225M, 2021)'],
    deal_size_range: '$10M - $300M acquisitions',
    preferred_stage: ['feasibility', 'pivotal_design'],
    source: 'Fulgent Annual Report 2024',
  },

  {
    company: 'Caris Life Sciences',
    company_type: 'diagnostics_specialty',
    hq: 'Irving, TX',
    market_cap_b: 0,
    revenue_b: 0.5,
    key_divisions: ['Molecular Profiling (MI Profile)', 'Whole Exome + Whole Transcriptome Sequencing'],
    primary_therapeutic_areas: ['oncology molecular profiling', 'WES+WTS', 'AI-guided treatment selection', 'clinical trial matching'],
    active_bd_interests: ['multi-omic profiling expansion', 'pharma partnerships for CDx', 'AI-driven biomarker discovery'],
    recent_acquisitions: ['Internal R&D focused; private company'],
    deal_size_range: '$10M - $500M partnerships',
    preferred_stage: ['feasibility', 'pivotal_design'],
    source: 'Caris corporate communications 2024',
  },

  // ── DIGITAL HEALTH / SaMD ─────────────────────────────────

  {
    company: 'Caption Health (GE)',
    company_type: 'digital_health',
    hq: 'Brisbane, CA (now GE HealthCare)',
    market_cap_b: 40,
    revenue_b: 0.05,
    key_divisions: ['AI Ultrasound Guidance', 'Automated Cardiac Assessment'],
    primary_therapeutic_areas: ['cardiology', 'point of care ultrasound', 'AI-guided imaging'],
    active_bd_interests: ['AI-guided ultrasound for non-specialists', 'cardiac screening expansion', 'primary care POC imaging'],
    recent_acquisitions: ['Acquired by GE HealthCare (2023)'],
    deal_size_range: '$5M - $300M partnerships',
    preferred_stage: ['cleared_approved', 'pivotal_design'],
    source: 'GE HealthCare / Caption Health 2024',
  },

  {
    company: 'Aidoc',
    company_type: 'digital_health',
    hq: 'Tel Aviv, Israel (US: New York)',
    market_cap_b: 0,
    revenue_b: 0.05,
    key_divisions: ['AI Radiology Triage', 'Always-On AI'],
    primary_therapeutic_areas: ['radiology AI', 'PE detection', 'ICH detection', 'cervical spine fracture'],
    active_bd_interests: ['new radiology AI modules', 'clinical workflow integration', 'health system partnerships'],
    recent_acquisitions: ['Internal AI development'],
    deal_size_range: '$5M - $100M partnerships',
    preferred_stage: ['cleared_approved'],
    source: 'Aidoc corporate communications 2024',
  },

  {
    company: 'HeartFlow',
    company_type: 'digital_health',
    hq: 'Mountain View, CA',
    market_cap_b: 0,
    revenue_b: 0.1,
    key_divisions: ['FFR-CT Analysis', 'AI Coronary Analysis'],
    primary_therapeutic_areas: ['coronary artery disease', 'non-invasive FFR', 'CT-derived hemodynamics'],
    active_bd_interests: ['next-gen cardiac CT analysis', 'plaque characterization AI', 'structural heart planning'],
    recent_acquisitions: ['Internal R&D focused'],
    deal_size_range: '$5M - $300M partnerships',
    preferred_stage: ['cleared_approved'],
    source: 'HeartFlow corporate communications 2024',
  },

  {
    company: 'Butterfly Network',
    company_type: 'digital_health',
    hq: 'Guilford, CT',
    market_cap_b: 0.3,
    revenue_b: 0.07,
    key_divisions: ['Butterfly iQ+ (handheld ultrasound)'],
    primary_therapeutic_areas: ['point-of-care ultrasound', 'primary care imaging', 'emergency medicine'],
    active_bd_interests: ['AI-guided ultrasound', 'developing world deployment', 'clinical workflow integration'],
    recent_acquisitions: ['Internal R&D focused'],
    deal_size_range: '$5M - $200M partnerships',
    preferred_stage: ['cleared_approved'],
    source: 'Butterfly Network Annual Report 2024',
  },

  {
    company: 'Senseonics Holdings',
    company_type: 'mid_medtech',
    hq: 'Germantown, MD',
    market_cap_b: 0.3,
    revenue_b: 0.02,
    key_divisions: ['Eversense CGM (Implantable)', 'Long-term Glucose Monitoring'],
    primary_therapeutic_areas: ['diabetes_metabolic', 'implantable CGM', 'T1 diabetes', 'T2 diabetes'],
    active_bd_interests: ['long-duration implantable CGM', 'next-gen sensor coatings', 'smartphone-integrated monitoring', 'insulin pump integration'],
    recent_acquisitions: ['Ascensia Diabetes Care (distribution partner, 2022)'],
    deal_size_range: '$10M - $500M',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Senseonics Annual Report 2024',
  },

  {
    company: 'Elekta',
    company_type: 'large_medtech',
    hq: 'Stockholm, Sweden',
    market_cap_b: 6,
    revenue_b: 1.8,
    key_divisions: ['Linear Accelerators', 'Brachytherapy', 'Treatment Management', 'Gamma Knife'],
    primary_therapeutic_areas: ['radiation oncology', 'radiosurgery', 'brachytherapy', 'MR-Linac'],
    active_bd_interests: ['MR-guided radiation therapy', 'AI treatment planning', 'adaptive radiotherapy', 'SBRT expansion'],
    recent_acquisitions: ['Kaiku Health (patient outcomes, 2022)'],
    deal_size_range: '$20M - $2B acquisitions',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Elekta Annual Report 2024',
  },

  // ── BATCH 2: ADDITIONAL COVERAGE (40 entries to reach 100+) ───

  {
    company: 'Abiomed (J&J)',
    company_type: 'large_medtech',
    hq: 'Danvers, MA (now J&J)',
    market_cap_b: 450,
    revenue_b: 1.2,
    key_divisions: ['Impella Heart Pumps', 'Percutaneous Heart Support'],
    primary_therapeutic_areas: ['cardiovascular', 'heart failure', 'interventional cardiology'],
    active_bd_interests: ['percutaneous ventricular assist', 'heart recovery monitoring', 'AI hemodynamic guidance'],
    recent_acquisitions: ['Acquired by J&J for $16.6B (2022)'],
    deal_size_range: '$50M - $17B',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'J&J MedTech 2024',
  },
  {
    company: 'Teleflex',
    company_type: 'large_medtech',
    hq: 'Wayne, PA',
    market_cap_b: 10,
    revenue_b: 2.9,
    key_divisions: ['Vascular Access', 'Interventional', 'Surgical', 'Anesthesia', 'Urology'],
    primary_therapeutic_areas: ['vascular', 'interventional', 'urology', 'anesthesia'],
    active_bd_interests: ['minimally invasive vascular access', 'interventional urology', 'AI-guided catheter placement'],
    recent_acquisitions: ['Standard Bariatrics ($305M, 2023)', 'Palette Life Sciences ($600M, 2023)'],
    deal_size_range: '$50M - $3B acquisitions',
    preferred_stage: ['cleared_approved', '510k_cleared'],
    source: 'Teleflex Annual Report 2024',
  },
  {
    company: 'Conmed Corporation',
    company_type: 'mid_medtech',
    hq: 'Largo, FL',
    market_cap_b: 3,
    revenue_b: 1.2,
    key_divisions: ['Orthopedics', 'General Surgery', 'AirSeal'],
    primary_therapeutic_areas: ['orthopedic', 'general_surgery', 'laparoscopy'],
    active_bd_interests: ['arthroscopic surgery', 'powered surgical instruments', 'smoke evacuation', 'sports medicine'],
    recent_acquisitions: ['In2Bones ($145M, 2022)', 'Biorez ($95M, 2023)'],
    deal_size_range: '$20M - $1B',
    preferred_stage: ['cleared_approved', '510k_cleared'],
    source: 'Conmed Annual Report 2024',
  },
  {
    company: 'NuVasive (Globus Medical)',
    company_type: 'large_medtech',
    hq: 'Audubon, PA (merged with Globus)',
    market_cap_b: 10,
    revenue_b: 2.4,
    key_divisions: ['Spine', 'Musculoskeletal Solutions', 'Enabling Technologies'],
    primary_therapeutic_areas: ['orthopedic', 'spine', 'robotics'],
    active_bd_interests: ['spine surgery robotics', 'AI surgical planning', 'expandable interbody devices', 'SI joint fusion'],
    recent_acquisitions: ['NuVasive + Globus Medical merger ($3.1B, 2023)'],
    deal_size_range: '$50M - $3B',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Globus Medical 2024',
  },
  {
    company: 'Artivion (CryoLife)',
    company_type: 'mid_medtech',
    hq: 'Kennesaw, GA',
    market_cap_b: 3,
    revenue_b: 0.4,
    key_divisions: ['Aortic Repair', 'Cardiac Surgery', 'Preserved Tissue'],
    primary_therapeutic_areas: ['cardiovascular', 'cardiac surgery', 'aortic repair'],
    active_bd_interests: ['endovascular aortic repair', 'preserved tissue solutions', 'minimally invasive cardiac surgery'],
    recent_acquisitions: ['Endospan ($207M, 2023)'],
    deal_size_range: '$20M - $500M',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Artivion Annual Report 2024',
  },
  {
    company: 'AngioDynamics',
    company_type: 'mid_medtech',
    hq: 'Latham, NY',
    market_cap_b: 0.5,
    revenue_b: 0.3,
    key_divisions: ['Auryon Atherectomy', 'NanoKnife Ablation', 'Vascular Access'],
    primary_therapeutic_areas: ['vascular', 'oncology_surgical', 'interventional'],
    active_bd_interests: ['irreversible electroporation (NanoKnife)', 'atherectomy devices', 'mechanical thrombectomy'],
    recent_acquisitions: ['Devoro Medical (thrombectomy, 2021)'],
    deal_size_range: '$10M - $300M',
    preferred_stage: ['cleared_approved', '510k_cleared'],
    source: 'AngioDynamics Annual Report 2024',
  },
  {
    company: 'Accuray',
    company_type: 'mid_medtech',
    hq: 'Sunnyvale, CA',
    market_cap_b: 0.3,
    revenue_b: 0.4,
    key_divisions: ['CyberKnife', 'TomoTherapy', 'iDMS Treatment Planning'],
    primary_therapeutic_areas: ['oncology_radiation', 'radiosurgery'],
    active_bd_interests: ['AI-adaptive radiation therapy', 'MR-guided radiation', 'SBRT optimization', 'prostate SBRT'],
    recent_acquisitions: ['Internal R&D focus on ClearRT imaging'],
    deal_size_range: '$10M - $500M',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Accuray Annual Report 2024',
  },
  {
    company: 'Merit Medical Systems',
    company_type: 'mid_medtech',
    hq: 'South Jordan, UT',
    market_cap_b: 5,
    revenue_b: 1.3,
    key_divisions: ['Cardiovascular', 'Endoscopy', 'Interventional Oncology'],
    primary_therapeutic_areas: ['cardiovascular', 'endoscopy_gi', 'interventional radiology'],
    active_bd_interests: ['drug-eluting beads', 'drainage catheters', 'biopsy devices', 'embolization'],
    recent_acquisitions: ['HeRO Graft business (Quiknode, 2022)'],
    deal_size_range: '$20M - $1B',
    preferred_stage: ['cleared_approved', '510k_cleared'],
    source: 'Merit Medical Annual Report 2024',
  },
  {
    company: 'Integer Holdings',
    company_type: 'mid_medtech',
    hq: 'Plano, TX',
    market_cap_b: 4,
    revenue_b: 1.6,
    key_divisions: ['Medical Devices (contract)', 'Electrochem Solutions'],
    primary_therapeutic_areas: ['cardiovascular', 'neurology', 'orthopedic'],
    active_bd_interests: ['implantable device components', 'battery technology for implants', 'catheter manufacturing', 'sensing technologies'],
    recent_acquisitions: ['Pulse Technologies (coating, 2021)'],
    deal_size_range: '$20M - $500M',
    preferred_stage: ['design_phase', 'cleared_approved'],
    source: 'Integer Annual Report 2024',
  },
  {
    company: 'Natus Medical (Integra neuro)',
    company_type: 'mid_medtech',
    hq: 'Middleton, WI (now Integra)',
    market_cap_b: 4,
    revenue_b: 0.5,
    key_divisions: ['Neurodiagnostic', 'Newborn Care', 'Neurosurgery'],
    primary_therapeutic_areas: ['neurology', 'neonatal', 'neurosurgery'],
    active_bd_interests: ['EEG monitoring', 'newborn hearing screening', 'neuromonitoring AI', 'epilepsy diagnostics'],
    recent_acquisitions: ['Acquired by Integra LifeSciences ($1.7B, 2019)'],
    deal_size_range: '$10M - $2B',
    preferred_stage: ['cleared_approved', '510k_cleared'],
    source: 'Integra LifeSciences 2024',
  },
  {
    company: 'Omnicell',
    company_type: 'mid_medtech',
    hq: 'Mountain View, CA',
    market_cap_b: 2,
    revenue_b: 1.1,
    key_divisions: ['Automated Dispensing', 'Central Pharmacy', 'EnlivenHealth'],
    primary_therapeutic_areas: ['pharmacy automation', 'medication management', 'health IT'],
    active_bd_interests: ['pharmacy robotics', 'AI medication adherence', 'cloud-based pharmacy platforms', 'specialty pharmacy automation'],
    recent_acquisitions: ['ReCept Pharmacy ($100M, 2022)', 'MarkeTouch Media (2022)'],
    deal_size_range: '$20M - $500M',
    preferred_stage: ['cleared_approved', 'commercial'],
    source: 'Omnicell Annual Report 2024',
  },
  {
    company: 'Varex Imaging',
    company_type: 'mid_medtech',
    hq: 'Salt Lake City, UT',
    market_cap_b: 1,
    revenue_b: 0.9,
    key_divisions: ['X-ray Tubes', 'Flat Panel Detectors', 'Software'],
    primary_therapeutic_areas: ['imaging_radiology', 'industrial imaging'],
    active_bd_interests: ['photon-counting detectors', 'AI image reconstruction', 'CT tube technology', 'dental imaging components'],
    recent_acquisitions: ['Internal R&D focus on photon-counting'],
    deal_size_range: '$10M - $300M',
    preferred_stage: ['design_phase', 'cleared_approved'],
    source: 'Varex Annual Report 2024',
  },
  {
    company: 'Cardiovascular Systems Inc (Abbott vascular)',
    company_type: 'mid_medtech',
    hq: 'St. Paul, MN (now Abbott)',
    market_cap_b: 200,
    revenue_b: 0.3,
    key_divisions: ['Orbital Atherectomy', 'Peripheral Vascular'],
    primary_therapeutic_areas: ['cardiovascular', 'vascular', 'peripheral artery disease'],
    active_bd_interests: ['orbital atherectomy', 'PAD intervention', 'calcified lesion treatment'],
    recent_acquisitions: ['Acquired by Abbott ($890M, 2023)'],
    deal_size_range: '$50M - $1B',
    preferred_stage: ['cleared_approved'],
    source: 'Abbott Vascular 2024',
  },
  {
    company: 'Lantheus Holdings',
    company_type: 'mid_medtech',
    hq: 'North Billerica, MA',
    market_cap_b: 6,
    revenue_b: 1.3,
    key_divisions: ['Radiopharmaceutical Diagnostics', 'AI Diagnostics'],
    primary_therapeutic_areas: ['imaging_radiology', 'oncology_radiation', 'cardiovascular'],
    active_bd_interests: ['PET imaging agents', 'PSMA-targeted diagnostics', 'AI-assisted nuclear medicine', 'theranostics'],
    recent_acquisitions: ['Perspective Therapeutics (investment, 2023)', 'POINT Biopharma collaboration'],
    deal_size_range: '$50M - $2B',
    preferred_stage: ['clinical_trial', 'cleared_approved'],
    source: 'Lantheus Annual Report 2024',
  },
  {
    company: 'Novocure',
    company_type: 'mid_medtech',
    hq: 'Root, Switzerland (US: Portsmouth, NH)',
    market_cap_b: 4,
    revenue_b: 0.6,
    key_divisions: ['Tumor Treating Fields (TTFields)', 'Optune'],
    primary_therapeutic_areas: ['oncology_radiation', 'glioblastoma', 'mesothelioma', 'NSCLC'],
    active_bd_interests: ['TTFields expansion to new tumor types', 'combination with immunotherapy', 'next-gen wearable TTFields arrays'],
    recent_acquisitions: ['Internal R&D (LUNAR, INNOVATE trials)'],
    deal_size_range: '$20M - $1B',
    preferred_stage: ['pivotal_ongoing', 'cleared_approved'],
    source: 'Novocure Annual Report 2024',
  },
  {
    company: 'AtriCure',
    company_type: 'mid_medtech',
    hq: 'Mason, OH',
    market_cap_b: 2,
    revenue_b: 0.4,
    key_divisions: ['Open Ablation', 'Minimally Invasive Ablation', 'Pain Management (cryo)'],
    primary_therapeutic_areas: ['cardiovascular', 'cardiac surgery', 'atrial fibrillation'],
    active_bd_interests: ['AF ablation devices', 'left atrial appendage management', 'cryoablation for pain', 'hybrid AF procedures'],
    recent_acquisitions: ['SentreHEART ($220M, 2021)'],
    deal_size_range: '$20M - $500M',
    preferred_stage: ['cleared_approved', '510k_cleared'],
    source: 'AtriCure Annual Report 2024',
  },
  {
    company: 'SI-BONE',
    company_type: 'mid_medtech',
    hq: 'Santa Clara, CA',
    market_cap_b: 2,
    revenue_b: 0.2,
    key_divisions: ['iFuse Implant System', 'SI Joint Fusion'],
    primary_therapeutic_areas: ['orthopedic', 'spine'],
    active_bd_interests: ['SI joint fusion', 'minimally invasive spine procedures', 'pelvic fixation'],
    recent_acquisitions: ['Internal R&D focus (iFuse TORQ)'],
    deal_size_range: '$10M - $300M',
    preferred_stage: ['cleared_approved'],
    source: 'SI-BONE Annual Report 2024',
  },
  {
    company: 'Zynex Medical',
    company_type: 'mid_medtech',
    hq: 'Lone Tree, CO',
    market_cap_b: 0.5,
    revenue_b: 0.2,
    key_divisions: ['Electrotherapy', 'NexWave', 'Fluid Monitoring'],
    primary_therapeutic_areas: ['pain management', 'rehabilitation', 'monitoring'],
    active_bd_interests: ['neurostimulation for pain', 'home-based monitoring', 'fluid status monitoring', 'TENS expansion'],
    recent_acquisitions: ['Kestrel Labs (pulse oximetry, 2020)'],
    deal_size_range: '$5M - $100M',
    preferred_stage: ['cleared_approved', '510k_cleared'],
    source: 'Zynex Annual Report 2024',
  },
  {
    company: 'LivaNova',
    company_type: 'mid_medtech',
    hq: 'London, UK',
    market_cap_b: 3,
    revenue_b: 1.1,
    key_divisions: ['Cardiopulmonary', 'Neuromodulation'],
    primary_therapeutic_areas: ['cardiovascular', 'neurology', 'epilepsy'],
    active_bd_interests: ['vagus nerve stimulation', 'cardiopulmonary bypass', 'drug-resistant epilepsy', 'treatment-resistant depression'],
    recent_acquisitions: ['ImThera Medical (hypoglossal nerve, 2018)'],
    deal_size_range: '$20M - $1B',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'LivaNova Annual Report 2024',
  },
  {
    company: 'ViewRay',
    company_type: 'mid_medtech',
    hq: 'Denver, CO',
    market_cap_b: 0.2,
    revenue_b: 0.1,
    key_divisions: ['MRIdian MR-guided Radiation Therapy'],
    primary_therapeutic_areas: ['oncology_radiation', 'MR-guided radiation'],
    active_bd_interests: ['MR-guided adaptive radiation therapy', 'real-time tumor tracking', 'pancreatic cancer radiation'],
    recent_acquisitions: ['Internal R&D focus on MRIdian platform'],
    deal_size_range: '$10M - $500M',
    preferred_stage: ['cleared_approved'],
    source: 'ViewRay 2024',
  },
  {
    company: 'Sensata Technologies',
    company_type: 'mid_medtech',
    hq: 'Attleboro, MA',
    market_cap_b: 8,
    revenue_b: 4.0,
    key_divisions: ['Sensors', 'Controls', 'Medical Sensors'],
    primary_therapeutic_areas: ['monitoring', 'sensor technology'],
    active_bd_interests: ['medical-grade sensors', 'pressure sensing for implants', 'wearable sensor components', 'IoT health monitoring'],
    recent_acquisitions: ['Dynapar (encoder, 2022)', 'Xirgo Technologies (2022)'],
    deal_size_range: '$20M - $1B',
    preferred_stage: ['design_phase', 'cleared_approved'],
    source: 'Sensata Annual Report 2024',
  },
  {
    company: 'ResMed',
    company_type: 'large_medtech',
    hq: 'San Diego, CA',
    market_cap_b: 35,
    revenue_b: 4.2,
    key_divisions: ['Sleep & Respiratory Care', 'SaaS (Brightree/MatrixCare)'],
    primary_therapeutic_areas: ['respiratory', 'sleep apnea', 'COPD'],
    active_bd_interests: ['connected respiratory devices', 'AI for sleep diagnosis', 'out-of-hospital SaaS platforms', 'mask innovation'],
    recent_acquisitions: ['MEDIFOX DAN ($1B, 2022)', 'Brightree acquisition (SaaS, 2016)'],
    deal_size_range: '$50M - $3B',
    preferred_stage: ['cleared_approved', 'commercial'],
    source: 'ResMed Annual Report 2024',
  },
  {
    company: 'Alcon',
    company_type: 'large_medtech',
    hq: 'Geneva, Switzerland (US: Fort Worth, TX)',
    market_cap_b: 40,
    revenue_b: 9.4,
    key_divisions: ['Surgical (Cataract/Vitreoretinal)', 'Vision Care (Contact Lenses)'],
    primary_therapeutic_areas: ['ophthalmology', 'cataract surgery', 'vitreoretinal'],
    active_bd_interests: ['premium IOLs', 'digital ophthalmology', 'presbyopia-correcting lenses', 'dry eye devices'],
    recent_acquisitions: ['Aerie Pharmaceuticals ($770M, 2022)', 'Ivantis (glaucoma, $475M, 2022)'],
    deal_size_range: '$50M - $3B',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Alcon Annual Report 2024',
  },
  {
    company: 'Coloplast',
    company_type: 'large_medtech',
    hq: 'Humlebaek, Denmark',
    market_cap_b: 25,
    revenue_b: 3.0,
    key_divisions: ['Ostomy Care', 'Continence Care', 'Wound Care', 'Interventional Urology'],
    primary_therapeutic_areas: ['wound_care', 'urology', 'ostomy'],
    active_bd_interests: ['advanced wound care', 'digital ostomy monitoring', 'BPH treatment devices', 'continence technology'],
    recent_acquisitions: ['Atos Medical ($2.1B, 2021)', 'Kerecis (fish skin wound care, $1.3B, 2023)'],
    deal_size_range: '$50M - $2B',
    preferred_stage: ['cleared_approved', '510k_cleared'],
    source: 'Coloplast Annual Report 2024',
  },
  {
    company: 'Olympus Corporation',
    company_type: 'large_medtech',
    hq: 'Tokyo, Japan (US: Center Valley, PA)',
    market_cap_b: 20,
    revenue_b: 7.5,
    key_divisions: ['Endoscopy', 'Therapeutic Solutions', 'Medical Systems'],
    primary_therapeutic_areas: ['endoscopy_gi', 'general_surgery', 'urology'],
    active_bd_interests: ['AI-assisted endoscopy', 'single-use endoscopes', 'endoscopic submucosal dissection', 'robotic endoscopy'],
    recent_acquisitions: ['Medi-Tate ($60M, 2022)', 'Quest Photonic (AI endoscopy, 2023)'],
    deal_size_range: '$50M - $2B',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Olympus Annual Report 2024',
  },
  {
    company: 'Solventum (3M Healthcare)',
    company_type: 'large_medtech',
    hq: 'Maplewood, MN',
    market_cap_b: 10,
    revenue_b: 8.3,
    key_divisions: ['Medical Surgical', 'Dental Solutions', 'Health Information Systems', 'Purification & Filtration'],
    primary_therapeutic_areas: ['wound_care', 'dental', 'infection prevention', 'health IT'],
    active_bd_interests: ['advanced wound care', 'surgical site infection prevention', 'health coding AI', 'dental digital workflows'],
    recent_acquisitions: ['Spun off from 3M (2024)', 'Internal R&D focus post-spinoff'],
    deal_size_range: '$50M - $2B',
    preferred_stage: ['cleared_approved', 'commercial'],
    source: 'Solventum 2024',
  },
  {
    company: 'Varian Medical (Siemens Healthineers)',
    company_type: 'large_medtech',
    hq: 'Palo Alto, CA (now Siemens Healthineers)',
    market_cap_b: 70,
    revenue_b: 3.5,
    key_divisions: ['Radiation Oncology', 'Interventional Solutions', 'Proton Therapy'],
    primary_therapeutic_areas: ['oncology_radiation', 'proton therapy', 'interventional radiology'],
    active_bd_interests: ['adaptive radiation therapy', 'AI treatment planning', 'flash therapy', 'proton therapy miniaturization'],
    recent_acquisitions: ['Acquired by Siemens Healthineers ($16.4B, 2021)'],
    deal_size_range: '$50M - $17B',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Siemens Healthineers 2024',
  },
  {
    company: 'Zimvie (Zimmer Biomet spin-off)',
    company_type: 'mid_medtech',
    hq: 'Palm Beach Gardens, FL',
    market_cap_b: 0.5,
    revenue_b: 0.5,
    key_divisions: ['Dental Implants', 'Spine'],
    primary_therapeutic_areas: ['dental', 'spine'],
    active_bd_interests: ['dental implant innovation', 'digital dentistry workflows', 'spine biologics', 'bone grafts'],
    recent_acquisitions: ['Spun off from Zimmer Biomet (2022)'],
    deal_size_range: '$10M - $300M',
    preferred_stage: ['cleared_approved', '510k_cleared'],
    source: 'Zimvie Annual Report 2024',
  },
  {
    company: 'Shockwave Medical (J&J vascular)',
    company_type: 'large_medtech',
    hq: 'Santa Clara, CA (now J&J)',
    market_cap_b: 450,
    revenue_b: 0.8,
    key_divisions: ['Intravascular Lithotripsy (IVL)', 'Coronary IVL', 'Peripheral IVL'],
    primary_therapeutic_areas: ['cardiovascular', 'vascular', 'interventional cardiology'],
    active_bd_interests: ['intravascular lithotripsy expansion', 'calcium modification', 'PAD treatment', 'structural heart'],
    recent_acquisitions: ['Acquired by J&J ($13.1B, 2024)'],
    deal_size_range: '$100M - $13B',
    preferred_stage: ['cleared_approved'],
    source: 'J&J MedTech 2024',
  },
  {
    company: 'Axonics (Boston Scientific neuromod)',
    company_type: 'large_medtech',
    hq: 'Irvine, CA (now Boston Scientific)',
    market_cap_b: 75,
    revenue_b: 0.4,
    key_divisions: ['Sacral Neuromodulation', 'Overactive Bladder'],
    primary_therapeutic_areas: ['urology', 'neuromodulation'],
    active_bd_interests: ['sacral neuromodulation', 'urinary incontinence devices', 'fecal incontinence', 'rechargeable neuromod'],
    recent_acquisitions: ['Acquired by Boston Scientific ($3.7B, 2024)'],
    deal_size_range: '$50M - $4B',
    preferred_stage: ['cleared_approved'],
    source: 'Boston Scientific 2024',
  },
  {
    company: 'Inspire Medical Systems',
    company_type: 'mid_medtech',
    hq: 'Golden Valley, MN',
    market_cap_b: 4,
    revenue_b: 0.8,
    key_divisions: ['Hypoglossal Nerve Stimulation'],
    primary_therapeutic_areas: ['respiratory', 'sleep apnea', 'neurology'],
    active_bd_interests: ['upper airway stimulation for OSA', 'next-gen sleep implants', 'pediatric OSA', 'sleep diagnostics'],
    recent_acquisitions: ['Internal R&D (Inspire V, next-gen platform)'],
    deal_size_range: '$20M - $1B',
    preferred_stage: ['cleared_approved', 'pivotal_ongoing'],
    source: 'Inspire Medical Annual Report 2024',
  },
  {
    company: 'Silk Road Medical (Boston Scientific)',
    company_type: 'mid_medtech',
    hq: 'Sunnyvale, CA (now Boston Scientific)',
    market_cap_b: 75,
    revenue_b: 0.2,
    key_divisions: ['Transcarotid Artery Revascularization (TCAR)', 'ENROUTE Neuroprotection'],
    primary_therapeutic_areas: ['cardiovascular', 'vascular', 'stroke prevention'],
    active_bd_interests: ['transcarotid stenting', 'neuroprotection systems', 'carotid artery disease'],
    recent_acquisitions: ['Acquired by Boston Scientific ($1.16B, 2024)'],
    deal_size_range: '$50M - $1.2B',
    preferred_stage: ['cleared_approved'],
    source: 'Boston Scientific 2024',
  },
  {
    company: 'Bionano Genomics',
    company_type: 'diagnostics_company',
    hq: 'San Diego, CA',
    market_cap_b: 0.1,
    revenue_b: 0.03,
    key_divisions: ['Saphyr Optical Genome Mapping', 'OGM Assays'],
    primary_therapeutic_areas: ['ivd_genetics', 'cytogenetics', 'hematology diagnostics'],
    active_bd_interests: ['optical genome mapping clinical adoption', 'hematologic malignancy diagnosis', 'structural variant detection'],
    recent_acquisitions: ['BioDiscovery (genomic analysis, 2022)'],
    deal_size_range: '$5M - $100M',
    preferred_stage: ['clinical_trial', 'cleared_approved'],
    source: 'Bionano Annual Report 2024',
  },
  {
    company: 'Personalis',
    company_type: 'diagnostics_company',
    hq: 'Menlo Park, CA',
    market_cap_b: 0.2,
    revenue_b: 0.08,
    key_divisions: ['NeXT Platform', 'ImmunoID NeXT', 'Whole-genome Profiling'],
    primary_therapeutic_areas: ['ivd_oncology', 'immuno-oncology diagnostics', 'ctDNA monitoring'],
    active_bd_interests: ['WGS-based tumor profiling', 'immuno-oncology biomarkers', 'MRD detection', 'pharma trial partnerships'],
    recent_acquisitions: ['Internal R&D (NeXT Liquid Biopsy)'],
    deal_size_range: '$5M - $200M',
    preferred_stage: ['clinical_trial', 'commercial'],
    source: 'Personalis Annual Report 2024',
  },
  {
    company: 'CareDx',
    company_type: 'diagnostics_company',
    hq: 'Brisbane, CA',
    market_cap_b: 1,
    revenue_b: 0.3,
    key_divisions: ['AlloSure (dd-cfDNA)', 'AlloMap', 'Transplant Diagnostics'],
    primary_therapeutic_areas: ['transplant diagnostics', 'rejection monitoring'],
    active_bd_interests: ['transplant rejection monitoring', 'multi-organ cfDNA testing', 'AI transplant risk prediction'],
    recent_acquisitions: ['Transplant Genomics (2021)'],
    deal_size_range: '$10M - $500M',
    preferred_stage: ['clinical_trial', 'cleared_approved'],
    source: 'CareDx Annual Report 2024',
  },
  {
    company: 'Seer Bio',
    company_type: 'diagnostics_company',
    hq: 'Redwood City, CA',
    market_cap_b: 0.3,
    revenue_b: 0.02,
    key_divisions: ['Proteograph Platform', 'Deep Proteomics'],
    primary_therapeutic_areas: ['proteomics', 'multi-omics diagnostics', 'oncology diagnostics'],
    active_bd_interests: ['deep proteomics at scale', 'multi-omics integration', 'biomarker discovery', 'pharma proteomics partnerships'],
    recent_acquisitions: ['Internal R&D (Proteograph XT, SP100 Automation)'],
    deal_size_range: '$5M - $200M',
    preferred_stage: ['research_use', 'clinical_trial'],
    source: 'Seer Annual Report 2024',
  },
  {
    company: 'Caris Life Sciences (private)',
    company_type: 'diagnostics_company',
    hq: 'Irving, TX',
    market_cap_b: 8,
    revenue_b: 0.8,
    key_divisions: ['Molecular Intelligence', 'Whole Exome Sequencing', 'Whole Transcriptome'],
    primary_therapeutic_areas: ['ivd_oncology', 'molecular profiling', 'precision oncology'],
    active_bd_interests: ['comprehensive genomic profiling', 'AI-driven treatment matching', 'liquid biopsy expansion', 'pharma biomarker partnerships'],
    recent_acquisitions: ['Multiple lab partnerships expansion (2023)'],
    deal_size_range: '$20M - $1B',
    preferred_stage: ['commercial', 'clinical_trial'],
    source: 'Caris Life Sciences 2024',
  },
  {
    company: 'Rapid Micro Biosystems',
    company_type: 'diagnostics_company',
    hq: 'Lowell, MA',
    market_cap_b: 0.1,
    revenue_b: 0.03,
    key_divisions: ['Growth Direct System', 'Rapid Sterility Testing'],
    primary_therapeutic_areas: ['ivd_infectious', 'pharmaceutical QC', 'sterility testing'],
    active_bd_interests: ['automated rapid sterility testing', 'environmental monitoring', 'pharma manufacturing QC', 'cell therapy QC'],
    recent_acquisitions: ['Internal R&D focus'],
    deal_size_range: '$5M - $100M',
    preferred_stage: ['commercial', 'cleared_approved'],
    source: 'Rapid Micro Annual Report 2024',
  },
  {
    company: 'Align Technology',
    company_type: 'large_medtech',
    hq: 'Tempe, AZ',
    market_cap_b: 20,
    revenue_b: 3.9,
    key_divisions: ['Invisalign', 'iTero Scanners'],
    primary_therapeutic_areas: ['dental', 'orthodontics'],
    active_bd_interests: ['AI treatment planning', 'intraoral scanning', 'digital orthodontics workflow', 'GP dentist expansion'],
    recent_acquisitions: ['Cubicure ($78M, 2023)', 'Internal R&D (Invisalign Palate Expander)'],
    deal_size_range: '$50M - $2B',
    preferred_stage: ['cleared_approved', 'commercial'],
    source: 'Align Technology Annual Report 2024',
  },
  {
    company: 'Envista Holdings',
    company_type: 'mid_medtech',
    hq: 'Brea, CA',
    market_cap_b: 3,
    revenue_b: 2.5,
    key_divisions: ['Nobel Biocare', 'KaVo Kerr', 'Ormco', 'Implant Direct'],
    primary_therapeutic_areas: ['dental', 'dental implants', 'orthodontics'],
    active_bd_interests: ['digital dental workflows', 'AI-guided implant placement', 'clear aligner technology', 'dental imaging'],
    recent_acquisitions: ['Spun off from Danaher (2019)', 'Osteon Medical (2021)'],
    deal_size_range: '$20M - $1B',
    preferred_stage: ['cleared_approved', '510k_cleared'],
    source: 'Envista Annual Report 2024',
  },

];

// ────────────────────────────────────────────────────────────
// COMBINED EXPORT — All device & diagnostics partners
// ────────────────────────────────────────────────────────────

export const DEVICE_PARTNER_DATABASE_FULL: DevicePartnerProfile[] = [
  ...EXISTING_DEVICE_PARTNERS,
  ...ADDITIONAL_DEVICE_PARTNERS,
];

// Re-export existing for backward compatibility
export { EXISTING_DEVICE_PARTNERS };
